ClinicalTrials.gg
CompletedNCT03321526Updated Apr 29, 2025Results posted

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

A Phase 2 interventional study of JNJ-42847922 and Placebo Matching to JNJ-42847922 in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 50 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
8th of 12
107 · median 176
Started
2017
with 1 other
Phase 2
2 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 8th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 4th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an antidepressant drug in delaying time to all-cause discontinuation of study drug over a 6-months (24 weeks) treatment period, in participants with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of non- (WONCBP) outpatients, aged 18 to 70 years (inclusive). A WONCBP is defined as: a).: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. b). Permanently sterile: Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy. c). If reproductive status is questionable, additional evaluation should be considered
  • Meet -5th Edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Structured Clinical Interview for DSM-5 Axis I Disorders- Clinical Trials Version (SCID-CT). The length of the current depressive episode must be less than or equal to (\<=) 18 months
  • Have had an inadequate response to at least 1 but no more than 3 antidepressants, administered at an adequate dose and duration in the current episode of depression, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ). An inadequate response is defined as less than (\<)50 percent (%) reduction in depressive symptom severity, as assessed by the MGH-ATRQ. An adequate trial is defined as an antidepressant treatment for at least 4 weeks at or above the minimum therapeutic dose, as specified in the MGH-ATRQ, for any particular antidepressant. The inadequate response must include the participant's current antidepressant treatment
  • Be receiving monotherapy treatment for depressive symptoms with 1 of the following selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants, in any formulation: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above the minimum therapeutic dose level) for at least 4 weeks, and for no greater than 12 months, at screening. Modification of an effective preexisting therapy should not be made for the explicit purpose of entering a participant into the study
  • Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to (>=)25 (performed by independent, centralized remote raters) at screening and must not demonstrate a improvement (that is, an improvement of greater than (>)20% on their MADRS total score) from the screening to baseline visit
  • Have a (BMI) between 18 and 35 kilogram per meter square (kg/m\^2) inclusive (BMI equal to [=] weight/height\^2)
  • Must be otherwise healthy on the basis of physical examination, medical history, vital signs, 12-lead (ECG), and clinical laboratory tests performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. If the results of the clinical laboratory tests are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Have Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the hypothalamic-pituitary-adrenal (HPA) axis
  • Have a history of epilepsy, neuroleptic malignant syndrome (NMS) or Tardive Dyskinesia
  • Have a history of previous non-response to an adequate trial of quetiapine as an adjunctive treatment for MDD (adequate trial defined as >=150 mg for 4 weeks or more) and/or a history of lack of response to 3 or more adequate antidepressant treatments and/or a history or evidence of noncompliance with current antidepressant therapy
  • Have taken a known moderate or strong inhibitor/inducer of cytochrome P450 (CYP)3A4 and CYP2C9 or a dual inhibitor/inducer of and CYP2C9 within 14 days (or after washout that is, duration of 5 times the drug's half-life) before the first study drug administration on Day 1 until the follow-up visit. Fluvoxamine is a moderate CYP2C9 inhibitor and a mild CYP3A inhibitor, and will not be excluded from the study
  • Have a history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders, or fibromyalgia
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    JNJ-42847922

    Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2\*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.

    Drug: JNJ-42847922 · Drug: Placebo Matching to JNJ-42847922 · Drug: Selective Serotonin Reuptake Inhibitor (SSRI) · Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

  • Active comparator
    Quetiapine Extended-Release (XR)

    Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2\*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.

    Drug: Quetiapine XR · Drug: Placebo Matching to Quetiapine XR · Drug: Selective Serotonin Reuptake Inhibitor (SSRI) · Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Interventions

  • Participants will receive JNJ-42847922 capsule orally.

    Also known as: MIN-202;, Seltorexant

  • DrugPlacebo Matching to JNJ-42847922

    Participants will receive placebo capsule matching to JNJ-42847922 orally.

  • Participants will receive quetiapine XR capsule orally.

  • DrugPlacebo Matching to Quetiapine XR

    Participants will receive placebo capsule matching to quetiapine XR orally.

  • Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).

  • DrugSerotonin-Norepinephrine Reuptake Inhibitor (SNRI)

    Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).

06

What researchers measure

Primary outcomes

  1. Time to All-Cause Discontinuation of Study Drug

    Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued.

    Time frame: Up to Week 24

Secondary outcomes

  1. Percentage of Participants With Sustained Remission up to Week 24

    Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

    Time frame: Up to Week 24

  2. Percentage of Participants With Sustained Response up to Week 24

    A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

    Time frame: Up to Week 24

  3. Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

    Time frame: Baseline and Week 12

  4. Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

    Time frame: Baseline and Week 18

  5. Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

    Time frame: Baseline and Week 24

  6. Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24

    HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12, 18, and 24

  7. Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24

    Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported.

    Time frame: At Week 24

  8. Percentage of Participants With Shifts in Triglycerides From Normal to High

    Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  9. Percentage of Participants With Shifts in Triglycerides From Borderline to High

    Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  10. Percentage of Participants With Shifts in Triglycerides From Normal to Very High

    Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  11. Percentage of Participants With Shifts in Triglycerides From Borderline to Very High

    Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  12. Percentage of Participants With Shifts in Triglycerides From High to Very High

    Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  13. Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline

    Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  14. Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High

    Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  15. Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High

    Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.

    Time frame: Up to Week 24

  16. Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24

    The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  17. Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24

    The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  18. Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24

    The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the present time", contains 34-items with "true"/"not true" response options. Each statement on the QLDS is given a score of "1" (adverse quality of life) or "0" good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  19. Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24

    The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  20. Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24

    The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  21. Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24

    The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 12 and 24

  22. Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24

    SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement.

    Time frame: Baseline, Weeks 6, 12, and 24

  23. Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24

    The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 6, 12, and 24

  24. Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24

    The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition.

    Time frame: Baseline, Weeks 6, 12, and 24

  25. Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24

    Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported.

    Time frame: Baseline, Weeks 6 and 24

  26. Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline.

    Time frame: Up to 24 weeks

  27. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias).

    Time frame: Up to 24 weeks

  28. Percentage of Participants With Abnormalities in Vital Sign Parameters

    Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.

    Time frame: Up to 24 weeks

  29. Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters

    Percentage of participants with abnormalities in ECG parameters were reported.

    Time frame: Up to 24 weeks

  30. Percentage of Participants With Abnormalities in Clinical Laboratory Parameters

    Percentage of participants with abnormalities in clinical laboratory parameters were reported.

    Time frame: Up to 24 weeks

  31. Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score

    Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.

    Time frame: Up to Endpoint (Up to 24 weeks)

  32. Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score

    The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity.

    Time frame: Up to Endpoint (Up to 24 weeks)

  33. Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score

    C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.

    Time frame: Up to Endpoint (Up to 24 weeks)

  34. Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)

    Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms.

    Time frame: Up to 26 weeks

  35. Change From Baseline in MADRS Total Score Over Time

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

    Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24

  36. Change From Baseline in MADRS Total Score Over Time, by Mode Dose

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26

  37. Change From Baseline in MADRS-6 Score Over Time

    MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition.

    Time frame: Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26

07

Results

Posted Aug 16, 2022
Limitations and caveats
As this was a flexibly dosed study, participants were not randomized into dose groups. History of intolerance or nonresponse to previous trials of quetiapine was an exclusion criterion, potentially biasing the sample. A discontinuation analysis by dose was confounded by the fact that participants were on the low dose for at least the first 14 days. As a result, a participant's dose could not reach a high mode dose until approximately 29 days from the start of treatment.

Participant flow

Double-blind Treatment Phase (24 Weeks)
Participant flow — Double-blind Treatment Phase (24 Weeks)
MilestoneSeltorexantQuetiapine XR
Started5453
Completed3027
Not completed2426
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject93
Withdrew: Lack of efficacy13
Withdrew: Adverse event78
Withdrew: Death10
Withdrew: Non-compliance with study drug36
Withdrew: Other14
Follow-up Phase (2 Weeks)
Participant flow — Follow-up Phase (2 Weeks)
MilestoneSeltorexantQuetiapine XR
Started5452
Completed3028
Not completed2424
Withdrew: Other2424

Outcome measures

PrimaryTime to All-Cause Discontinuation of Study Drug

Time to all-cause discontinuation of study drug is defined as the number of days from the first dose of study drug to the last dose of study drug. Participants who completed double-blind treatment were not considered to have discontinued.

Time frame:
Up to Week 24
Reported as:
Median · days
Time to All-Cause Discontinuation of Study Drug
daysSeltorexantQuetiapine XR
Time to All-Cause Discontinuation of Study DrugNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Seltorexant vs Quetiapine XR · Log Rank · p = 0.5355
SecondaryPercentage of Participants With Sustained Remission up to Week 24

Remission is defined as Montgomery-Asberg Depression Rating Scale (MADRS) total score of less than or equal to (\<=) 12. A participant was defined as having achieved sustained remission if the MADRS total score was ≤12 at Week 12 and was sustained at Weeks 18 and 24. Participants with missing values at a given time point were imputed as non-evaluable for remission. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Remission up to Week 24
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Sustained Remission up to Week 2413.219.4
SecondaryPercentage of Participants With Sustained Response up to Week 24

A participant was defined as having achieved a sustained response if there was at least a 50% improvement from baseline in the MADRS total score at Week 12, and that response was maintained at Week 18 and Week 24. Participants who did not meet such criterion were considered as non-sustained responders. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Response up to Week 24
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Sustained Response up to Week 2413.222.2
SecondaryChange From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline Insomnia Severity Index [ISI] Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score Less Than [<] 15) at Week 12
score on a scaleSeltorexantQuetiapine XR
Baseline ISI score <15-10.4 ± 12.68-12.8 ± 9.67
Baseline ISI score >=15-13.4 ± 10.73-17.3 ± 9.70
SecondaryChange From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

Time frame:
Baseline and Week 18
Reported as:
Mean · score on a scale
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISI Score >=15) Versus Those Without Significant Insomnia (Baseline ISI Score <15) at Week 18
score on a scaleSeltorexantQuetiapine XR
Baseline ISI score <15-13.9 ± 16.66-16.2 ± 10.46
Baseline ISI score >=15-10.3 ± 14.96-12.9 ± 11.58
SecondaryChange From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in MADRS Total Score in Participants With Significant Insomnia (Baseline ISIscore >=15) Versus Those Without Significant Insomnia (Baseline ISI Score 15) at Week 24
score on a scaleSeltorexantQuetiapine XR
Baseline ISI score <15-14.3 ± 14.47-15.6 ± 8.78
Baseline ISI score >=15-13.5 ± 14.32-15.4 ± 11.76
SecondaryChange From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24

HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12, 18, and 24
Reported as:
Mean · units on a scale
Change From Baseline in the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Weeks 12, 18, and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-8.7 ± 6.05-6.6 ± 6.75
Week 18-8.5 ± 6.66-10.0 ± 5.69
Week 24-10.9 ± 6.55-9.5 ± 7.26
SecondaryPercentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24

Percentage of participants with weight gain of \>=7% of baseline body weight at Week 24 were reported.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 24
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Weight Gain of >=7% of Baseline Body Weight at Week 244.38.5
SecondaryPercentage of Participants With Shifts in Triglycerides From Normal to High

Percentage of participants with shifts in triglycerides from normal to high (\<150 milligrams per deciliter \[mg/dL\] at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Triglycerides From Normal to High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Triglycerides From Normal to High7.113.6
SecondaryPercentage of Participants With Shifts in Triglycerides From Borderline to High

Percentage of participants with shifts in triglycerides from borderline to high (\>=150 to \<200 mg/dL at baseline to \>=200 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Triglycerides From Borderline to High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Triglycerides From Borderline to High25.037.5
SecondaryPercentage of Participants With Shifts in Triglycerides From Normal to Very High

Percentage of participants with shifts in triglycerides from normal to very high (\<150 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Triglycerides From Normal to Very High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Triglycerides From Normal to Very High00
SecondaryPercentage of Participants With Shifts in Triglycerides From Borderline to Very High

Percentage of participants with shifts in triglycerides from borderline to very high (\>=150 mg/dL to \<200 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Triglycerides From Borderline to Very High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Triglycerides From Borderline to Very High00
SecondaryPercentage of Participants With Shifts in Triglycerides From High to Very High

Percentage of participants with shifts in triglycerides from high to very high (\>=200 mg/dL to \<500 mg/dL at baseline to \>=500 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Triglycerides From High to Very High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Triglycerides From High to Very High16.70
SecondaryPercentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline

Percentage of participants with shifts in fasting blood glucose from normal to borderline (\<100 mg/dL at baseline to between \>=100 and \<126 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to Borderline38.736.0
SecondaryPercentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High

Percentage of participants with shifts in fasting blood glucose from borderline to high (\>=100 to \<126 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Fasting Blood Glucose From Borderline to High9.125.0
SecondaryPercentage of Participants With Shifts in Fasting Blood Glucose From Normal to High

Percentage of participants with shifts in fasting blood glucose from normal to high (\<100 mg/dL at baseline to \>=126 mg/dL at any post-baseline assessment) were reported.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Shifts in Fasting Blood Glucose From Normal to High3.24.0
SecondaryChange From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24

The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Scale Score at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-1.2 ± 1.39-1.7 ± 1.23
Week 24-1.4 ± 1.65-1.7 ± 1.10
SecondaryChange From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24

The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in the Patient Global Impression Severity (PGI-S) Scale Score at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-1.0 ± 1.07-1.1 ± 1.02
Week 24-1.2 ± 1.10-1.5 ± 1.09
SecondaryChange From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24

The QLDS is a disease specific patient-reported outcome (PRO) designed to assess health related quality of life in participants with major depressive disorder (MDD). The instrument has a recall period of "at the present time", contains 34-items with "true"/"not true" response options. Each statement on the QLDS is given a score of "1" (adverse quality of life) or "0" good quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life in Depression Scale (QLDS) Score at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-8.1 ± 9.20-8.3 ± 8.68
Week 24-9.5 ± 10.32-9.9 ± 10.43
SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24

The PROMIS-SD Short Form 8a subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-8.22 ± 10.073-11.87 ± 10.717
Week 24-11.45 ± 11.722-12.91 ± 7.878
SecondaryChange From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24

The PROMIS-SRI Short Form 8a subscale consists of a static 8 item questionnaire and use five-point likert scale to capture the participant's impressions. It assesses sleep-related impairment over the past 7 days. Responses to each of the 8 items range from 1 (less impairment) to 5 (more impairment), and the range of possible summed raw scores is 8 to 40. Lower scores indicate less sleep related impairment. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Patient Reported Outcomes Measurement Information System-Sleep Related Impairment (PROMIS-SRI) Short Form 8a at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-7.25 ± 9.449-9.09 ± 7.992
Week 24-11.02 ± 11.061-10.74 ± 6.970
SecondaryChange From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24

The SMDDS assesses participant-reported symptoms associated with MDD. This 16-item instrument has a 7-day recall period, and participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") are combined into a single score by selecting the highest severity on either item. The total score is then created by summing the responses on the 15 items. The total score ranges from 0 to 60 with a higher score indicating more severe depressive symptomatology. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Score at Weeks 12 and 24
units on a scaleSeltorexantQuetiapine XR
Week 12-13.9 ± 10.92-15.7 ± 11.16
Week 24-15.6 ± 13.07-19.6 ± 11.59
SecondaryChange From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24

SDMT is a widely used, paper-and-pencil assessment of complex scanning and visual tracking, requiring elements of attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The test is viewed as a robust screening test for adult neuropsychological impairment and is sensitive to impairments in cognitive function associated with MDD. The SDMT measured the time to pair abstract symbols with specific numbers. The test included a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. Following the key, the participant was presented with randomly ordered symbols and was required to write the number corresponding to each symbol as fast as possible. The number of correct substitutions within 90 seconds was recorded and total score derived from the total number of correct responses with a minimum possible score of 0 and maximum of 110 where high scores indicate better outcome. Positive change in score indicates improvement.

Time frame:
Baseline, Weeks 6, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Symbol Digit Modalities Test (SDMT) at Weeks 6, 12, and 24
units on a scaleSeltorexantQuetiapine XR
Week 65.0 ± 14.45-2.9 ± 11.72
Week 125.5 ± 17.610.1 ± 14.07
Week 244.7 ± 18.780.0 ± 9.83
SecondaryChange From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24

The TMT-Part B measures divided attention and executive function (tracking and sequencing). The participant is instructed to draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters (that is, 1 A 2 B). The participant is instructed to work as quickly as possible while still maintaining accuracy. Score included time (seconds) to completion and number of errors in performing the test which ranges from 0 (no errors) to 25 (more errors), where shorter time and less number of errors indicates better performance. The TMT-Part B is sensitive to cognitive decline associated with MDD. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 6, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Trail Making Test - Part B (TMT-Part B) at Weeks 6, 12, and 24
units on a scaleSeltorexantQuetiapine XR
Week 60.4 ± 3.260.0 ± 2.59
Week 120.2 ± 3.390.6 ± 2.93
Week 240.5 ± 4.54-0.3 ± 1.54
SecondaryChange From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24

The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0 -12); the total number of true-positive errors (0-12); and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score indicates higher cognition.

Time frame:
Baseline, Weeks 6, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Weeks 6, 12, and 24
units on a scaleSeltorexantQuetiapine XR
Total Recall: Week 60.6 ± 4.60-0.1 ± 5.51
Total Recall: Week 121.9 ± 5.241.3 ± 5.25
Total Recall: Week 242.0 ± 5.221.4 ± 5.09
Delayed Recall: Week 60.2 ± 2.070.6 ± 2.57
Delayed Recall: Week 120.5 ± 2.541.0 ± 2.52
Delayed Recall: Week 241.3 ± 2.741.4 ± 2.39
Total True-Positive Errors: Week 60.5 ± 4.21-0.4 ± 2.71
Total True-Positive Errors: Week 120.2 ± 3.99-0.1 ± 3.59
Total True-Positive Errors: Week 240.5 ± 3.03-0.7 ± 3.07
Recognition Discrimination Index: Week 60.8 ± 4.031.0 ± 3.80
Recognition Discrimination Index: Week 12-0.3 ± 4.670.1 ± 5.29
Recognition Discrimination Index: Week 240.9 ± 2.91-0.3 ± 4.69
SecondaryChange From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24

Change from baseline in salivary cortisol levels as measured upon awakening and at home during the evening at Weeks 6 and 24 were reported.

Time frame:
Baseline, Weeks 6 and 24
Reported as:
Mean · nanomoles per liter (nmol/L)
Change From Baseline in Salivary Cortisol Levels as Measured at Home Upon Awakening and During the Evening at Weeks 6 and 24
nanomoles per liter (nmol/L)SeltorexantQuetiapine XR
Awakening: Week 61.3 ± 9.07-2.8 ± 8.27
Awakening: Week 241.4 ± 9.42-1.7 ± 6.86
Evening: Week 6-0.7 ± 4.590.5 ± 5.96
Evening: Week 241.4 ± 6.850.9 ± 2.73
SecondaryPercentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were AEs with onset during the double-blind treatment phase or that were a consequence of a preexisting condition that worsened since baseline.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability65.480.8
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Adverse events of special interest were cataplexy, sleep paralysis, complex, and sleep-related behaviors (parasomnias).

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Events of Special Interest
percentage of participantsSeltorexantQuetiapine XR
SAEs1.93.8
AESIs13.55.8
SecondaryPercentage of Participants With Abnormalities in Vital Sign Parameters

Percentage of participants with abnormalities in vital sign parameters (pulse, supine and standing blood pressure \[systolic and diastolic\], body temperature, and body weight) were reported. Abnormally low values for parameters included pulse (beats per minute)- decrease value from baseline (\>=) 15 to \<=50; Systolic Blood Pressure (BP) (mmHg \[Millimeter of mercury\])- decrease value from baseline \>=20 to \<=90; Diastolic BP- decrease value from baseline \>=15 to \<=50; weight (Kilogram\[Kg\])- decrease from baseline of \>=7%; Body temperature (Celsius \[C\])- \<35.5. Abnormally high values for parameters included pulse- increase value from baseline \>=15 to \>=100; Systolic BP(mmHg)- increase from baseline of \>=20 to \>=180; Diastolic BP- increase value from baseline \>=15 to \>=105; weight(Kg)- increase from baseline of \>=7%; body temperature (C)- \>37.5.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormalities in Vital Sign Parameters
percentage of participantsSeltorexantQuetiapine XR
Supine Pulse Rate: Abnormally low02.0
Supine Pulse Rate: Abnormally high2.03.9
Standing Pulse Rate: Abnormally low00
Standing Pulse Rate: Abnormally high2.05.9
Supine Systolic Blood Pressure: Abnormally low00
Supine Systolic Blood Pressure: Abnormally high00
Standing Systolic Blood Pressure: Abnormally low02.0
Standing Systolic Blood Pressure: Abnormally high00
Supine Diastolic Blood Pressure: Abnormally low00
Supine Diastolic Blood Pressure: Abnormally high00
Standing Diastolic Blood Pressure: Abnormally low00
Standing Diastolic Blood Pressure: Abnormally high2.00
Temperature: Abnormally low00
Temperature: Abnormally high6.00
Weight: Abnormally low4.30
Weight: Abnormally high4.38.5
SecondaryPercentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters

Percentage of participants with abnormalities in ECG parameters were reported.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Abnormalities in Electrocardiogram (ECG) Parameters00
SecondaryPercentage of Participants With Abnormalities in Clinical Laboratory Parameters

Percentage of participants with abnormalities in clinical laboratory parameters were reported.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Abnormalities in Clinical Laboratory Parameters00
SecondaryPercentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score

Sexual dysfunction is defined as an ASEX total score of 19 or greater, or a score of 5 or greater on any item, or a score of 4 or greater on any 3 items. ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point Likert scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.

Time frame:
Up to Endpoint (Up to 24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Total Score64.375.6
SecondaryPercentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score

The ESRS-A is an abbreviated manualized version of the ESRS, a semi-structured interview that rates parkinsonian symptoms, dystonia, dyskinesias, and akathisia over the previous 7 days. The ratings include a motor examination for rigidity, tremor, reduced facial expression or speech, impaired gait/posture, postural instability, and bradykinesia/hypokinesia. Twenty-four individual items are rated on a 6-point scale: 0=Absent, 1=Minimal, 2=Mild, 3=Moderate, 4=Severe, or 5=Extreme. Frequency is included as an index of severity.

Time frame:
Up to Endpoint (Up to 24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score
percentage of participantsSeltorexantQuetiapine XR
Percentage of Participants With Clinically Relevant Changes in Extrapyramidal Symptoms Assessed by the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Score00
SecondaryPercentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score

C-SSRS is a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt \[non-fatal\]), and 10 (completed suicide \[only applicable for post baseline\]). Minimum total score 0, maximum total score 10; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.

Time frame:
Up to Endpoint (Up to 24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Suicidality Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) Score
percentage of participantsSeltorexantQuetiapine XR
0=No Event100100
1=Wish to be Dead00
2 = Non-Specific Active Suicidal Thoughts00
3 = Suicidal Ideation Without Plan and Intent00
4 = Suicidal Ideation Intent to Act Without Plan00
5 = Suicidal Ideation With Plan and Intent00
6 = Preparatory Acts or Behavior00
7 = Aborted Attempt00
8 = Interrupted Attempt00
9 = Actual Attempt00
10 = Completed Suicide00
SecondaryPercentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)

Intensity of discontinuation symptoms was assessed (anxiety-nervousness, dysphoric mood/depression, Depersonalization-Derealization, , Diaphoresis, Diarrhea, Difficulty Concentrating, Remember, Dizziness-Lightheadedness, Fatigue-Lethargy-Lack of Energy, Headaches, Increased Acuity Sound Smell Touch, Irritability, Loss of Appetite, Muscle Aches or Stiffness, Nausea-Vomiting, Paresthesias, Poor Coordination, Restlessness-Agitation, Tremor-Tremulousness, Weakness), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale of 0 (no symptom present), 1 (mild), 2 (moderate), and 3 (severe). Total scores range from 0 (no symptom) to 24 (severe symptom) calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicates more severe symptoms.

Time frame:
Up to 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participant With Potential Withdrawal Effects Assessed by the Physician Withdrawal Checklist (PWC)
percentage of participantsSeltorexantQuetiapine XR
Anxiety-Nervousness present (Endpoint [DB])75.033.3
Anxiety-Nervousness present (Follow-up)33.353.6
Depersonalization-Derealization present (Endpoint [DB])00
Depersonalization-Derealization present (Follow-up)6.70
Diaphoresis present (Endpoint [DB])00
Diaphoresis present (Follow-up)6.710.7
Diarrhea present (Endpoint [DB])00
Diarrhea present (Follow-up)014.3
Difficulty Concentrating, Remembering present (Endpoint [DB])00
Difficulty Concentrating, Remembering present (Follow-up)26.739.3
Dizziness-Lightheadedness present (Endpoint [DB])033.3
Dizziness-Lightheadedness present (Follow-up)23.385.7
Dysphoric Mood-Depression present (Endpoint [DB])50.066.7
Dysphoric Mood-Depression present (Follow-up)40.060.7
Fatigue-Lethargy-Lack of Energy present (Endpoint[DB])50.066.7
Fatigue-Lethargy-Lack of Energy present (Follow-up)33.339.3
Headaches present (Endpoint [DB])033.3
Headaches present (Follow-up)16.732.1
Increased Acuity for Sound, Smell, Touch, or Pain present (Endpoint [DB])00
Increased Acuity for Sound, Smell, Touch, or Pain present (Follow-up)6.77.1
Insomnia present (Endpoint [DB])75.066.7
Insomnia present (Follow-up)33.346.4
Irritability present (Endpoint [DB])75.066.7
Irritability present (Follow-up)23.325.0
Loss of Appetite present (Endpoint [DB])25.066.7
Loss of Appetite present (Follow-up)10.021.4
Muscle Aches or Stiffness present (Endpoint [DB])50.033.3
Muscle Aches or Stiffness present (Follow-up)16.714.3
Nausea-Vomiting present (Endpoint [DB])00
Nausea-Vomiting present (Follow-up)3.317.9
Paresthesias present (Endpoint [DB])00
Paresthesias present (Follow-up)3.33.6
Poor Coordination present (Endpoint [DB])25.033.3
Poor Coordination present (Follow-up)10.085.7
Restlessness-Agitation present (Endpoint [DB])25.033.3
Restlessness-Agitation present (Follow-up)26.710.7
Tremor-Tremulousness present (Endpoint [DB])033.3
Tremor-Tremulousness present (Follow-up)3.314.3
Weakness present (Endpoint [DB])25.033.3
Weakness present (Follow-up)3.314.3
SecondaryChange From Baseline in MADRS Total Score Over Time

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.

Time frame:
Baseline, Weeks 2, 4, 6, 12, 18, 24
Reported as:
Mean · score on a scale
Change From Baseline in MADRS Total Score Over Time
score on a scaleSeltorexantQuetiapine XR
Week 2-6.7 ± 9.00-6.4 ± 8.00
Week 4-8.7 ± 9.71-10.8 ± 9.60
Week 6-9.9 ± 9.98-11.4 ± 9.40
Week 12-12.3 ± 11.41-15.6 ± 9.80
Week 18-11.7 ± 15.48-14.1 ± 11.41
Week 24-13.8 ± 14.13-15.4 ± 10.57
SecondaryChange From Baseline in MADRS Total Score Over Time, by Mode Dose

MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
Reported as:
Mean · score on a scale
Change From Baseline in MADRS Total Score Over Time, by Mode Dose
score on a scaleSeltorexant 20 mgSeltorexant 40 mgQuetiapine XR 150 mgQuetiapine XR 300 mg
Week 2-7.3 ± 7.28-2.4 ± 5.66-4.5 ± 5.80-3.6 ± 5.49
Week 4-7.7 ± 8.05-4.4 ± 6.25-6.9 ± 6.99-6.9 ± 6.79
Week 6-9.1 ± 9.26-5.2 ± 6.26-7.3 ± 5.67-7.6 ± 7.82
Week 12-11.8 ± 9.34-5.3 ± 6.69-12.5 ± 6.87-9.3 ± 7.99
Week 18-12.8 ± 9.98-3.8 ± 9.64-6.0 ± 8.26-10.5 ± 8.61
Week 24-14.9 ± 7.93-5.2 ± 8.38-11.9 ± 6.06-9.7 ± 9.53
Week 26-16.3 ± 7.52-9.3 ± 8.98-8.3 ± 7.10-8.6 ± 8.45
SecondaryChange From Baseline in MADRS-6 Score Over Time

MADRS-6 is the depression subscale of the full MADRS, including the following 6 items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, pessimistic thoughts. Each item is scored from 0 (absence of symptom) to 6 (severe symptom); the overall score ranges from 0 to 36 which is calculated by adding the scores of all 6 items. Higher scores represent a more severe condition.

Time frame:
Baseline, Weeks 2, 4, 6, 12, 18, 24, and 26
Reported as:
Mean · score on a scale
Change From Baseline in MADRS-6 Score Over Time
score on a scaleSeltorexantQuetiapine XR
Week 2-4.4 ± 6.76-4.1 ± 5.60
Week 4-5.8 ± 7.18-6.9 ± 6.79
Week 6-6.7 ± 7.69-7.5 ± 6.95
Week 12-7.5 ± 8.18-10.4 ± 7.68
Week 18-7.2 ± 10.60-9.2 ± 8.62
Week 24-9.1 ± 9.40-10.3 ± 8.59
Week 26-9.1 ± 8.97-8.4 ± 7.83

Adverse events

Collected over Up to 26 weeks for serious and other (non-serious) adverse events and up to 30 weeks for all-cause mortality. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind: Seltorexant1/52 (1.9%)1/52 (1.9%)21/52 (40.4%)
Double-blind: Quetiapine XR0/52 (0%)2/52 (3.8%)32/52 (61.5%)
Follow-up: Seltorexant0/52 (0%)0/52 (0%)1/52 (1.9%)
Follow-up: Quetiapine XR0/52 (0%)0/52 (0%)2/52 (3.8%)
Most frequent serious events
Most frequent serious events
EventDouble-blind: SeltorexantDouble-blind: Quetiapine XRFollow-up: SeltorexantFollow-up: Quetiapine XR
Atrial FlutterCardiac disorders1/520/520/520/52
Spinal Column StenosisMusculoskeletal and connective tissue disorders0/521/520/520/52
Suicide AttemptPsychiatric disorders0/521/520/520/52
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/520/520/520/52
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDouble-blind: SeltorexantDouble-blind: Quetiapine XRFollow-up: SeltorexantFollow-up: Quetiapine XR
Dry MouthGastrointestinal disorders3/5213/520/520/52
SomnolenceNervous system disorders6/5211/520/520/52
Abnormal DreamsPsychiatric disorders7/521/520/520/52
FatigueGeneral disorders2/524/520/520/52
Weight IncreasedInvestigations4/523/520/521/52
DiarrhoeaGastrointestinal disorders0/523/520/521/52
NauseaGastrointestinal disorders0/523/520/520/52
VomitingGastrointestinal disorders0/523/520/521/52
BronchitisInfections and infestations1/523/520/520/52
HeadacheNervous system disorders3/521/521/520/52

Baseline characteristics

The safety analysis set included all randomized participants who received at least 1 dose of study drug including the 2 participants who received the potentially defective investigational product (IP).

Age, Continuous
Age, Continuous(years)SeltorexantQuetiapine XRTotal
Mean55.3 ± 9.6753.6 ± 10.8354.5 ± 10.26
Age, Customized
Age, Customized(Participants)SeltorexantQuetiapine XRTotal
Adults (18-64 years)434386
From 65 to 84 years9918
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)SeltorexantQuetiapine XRTotal
Female343569
Male181735
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SeltorexantQuetiapine XRTotal
Hispanic or Latino171027
Not Hispanic or Latino344175
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SeltorexantQuetiapine XRTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander202
Black or African American141428
White363672
More than one race022
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)SeltorexantQuetiapine XRTotal
UNITED STATES5252104
08

Study locations

50 sites
  • NoesisPharma Research
    Phoenix, Arizona 85032, United States
  • Clinical Research Consortium Arizona
    Tempe, Arizona 85283, United States
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • Collaborative NeuroScience Network
    Garden Grove, California 92845, United States
  • Pacific Institute of Medical Sciences
    Los Angeles, California 90024, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Excell Research Inc
    Oceanside, California 92056, United States
  • Desert Valley Research
    Rancho Mirage, California 92270, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Research Center for Clinical Studies, Inc.
    Norwalk, Connecticut 06851, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • SIH Research
    Kissimmee, Florida 34759, United States
  • Premier Clinical Research
    Miami, Florida 33122, United States
  • Innova Clinical Trials
    Miami, Florida 33133, United States
  • Arocha Research Center Inc
    Miami, Florida 33145, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Suburban Clinical Research Group, Inc
    Bolingbrook, Illinois 60490, United States
  • RxClinicals
    Crystal Lake, Illinois 60012, United States
  • Alexian Brothers Health System
    Hoffman Estates, Illinois 60169, United States
  • Psychiatric Medicine Associates LLC
    Skokie, Illinois 60076, United States
  • American Research, LLC
    Jeffersonville, Indiana 47130, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Phoenix Medical Research, Inc.
    Prairie Village, Kansas 66208, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21218, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • Boston Clinical Trials & Medical Research
    Roslindale, Massachusetts 02135, United States
  • Rochester Center for Behavioral Medicine (RCBM)
    Rochester Hills, Michigan 48307, United States
  • Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • PsychCare Consultants Research
    Saint Louis, Missouri 63128, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119-5190, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • CNS Research Science, Inc.
    Jamaica, New York 11432, United States
  • Hapworth Psychiatric Medical PLLC
    New York, New York 10019, United States
  • Carolina Partners c/o Tripha Life Sciences
    Raleigh, North Carolina 27606, United States
  • Patient Priority Clinical Sites LLC
    Cincinnati, Ohio 45215, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • BTC Network
    Lincoln, Rhode Island 02865, United States
  • Hawkins Psychiatry, PC
    Arlington, Texas 76013, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Houston Endoscopy and Research Center, Inc.
    Houston, Texas 77079, United States
  • Texas Center for Drug Development Inc
    Houston, Texas 77081, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • Ericksen Research and Development
    Clinton, Utah 84015, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2019, 18 months.

Results were first posted in Aug 2022, 3 years 2 months after primary completion. A results delay was requested in Jun 2020.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 18 months is close to that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2017
First posted
Oct 25, 2017
StartActual
Dec 12, 2017
Primary completionActual
Jun 13, 2019
CompletionActual
Jun 27, 2019
Results delay requested
Jun 10, 2020
Results first posted
Aug 16, 2022
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03321526
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Dec 12, 2017
Primary completion
Jun 13, 2019
Completion
Jun 27, 2019
Results posted
Aug 16, 2022
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion